1. Home
  2. CELC vs IONR Comparison

CELC vs IONR Comparison

Compare CELC & IONR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • IONR
  • Stock Information
  • Founded
  • CELC 2011
  • IONR 2001
  • Country
  • CELC United States
  • IONR Australia
  • Employees
  • CELC N/A
  • IONR N/A
  • Industry
  • CELC Medical Specialities
  • IONR
  • Sector
  • CELC Health Care
  • IONR
  • Exchange
  • CELC Nasdaq
  • IONR Nasdaq
  • Market Cap
  • CELC 327.3M
  • IONR 262.0M
  • IPO Year
  • CELC 2017
  • IONR N/A
  • Fundamental
  • Price
  • CELC $11.62
  • IONR $3.50
  • Analyst Decision
  • CELC Strong Buy
  • IONR
  • Analyst Count
  • CELC 5
  • IONR 0
  • Target Price
  • CELC $30.80
  • IONR N/A
  • AVG Volume (30 Days)
  • CELC 148.5K
  • IONR 6.4K
  • Earning Date
  • CELC 05-14-2025
  • IONR 01-01-0001
  • Dividend Yield
  • CELC N/A
  • IONR N/A
  • EPS Growth
  • CELC N/A
  • IONR N/A
  • EPS
  • CELC N/A
  • IONR N/A
  • Revenue
  • CELC N/A
  • IONR N/A
  • Revenue This Year
  • CELC N/A
  • IONR N/A
  • Revenue Next Year
  • CELC N/A
  • IONR N/A
  • P/E Ratio
  • CELC N/A
  • IONR N/A
  • Revenue Growth
  • CELC N/A
  • IONR N/A
  • 52 Week Low
  • CELC $7.58
  • IONR $3.02
  • 52 Week High
  • CELC $19.77
  • IONR $9.35
  • Technical
  • Relative Strength Index (RSI)
  • CELC 64.24
  • IONR 47.47
  • Support Level
  • CELC $10.50
  • IONR $3.23
  • Resistance Level
  • CELC $10.88
  • IONR $3.67
  • Average True Range (ATR)
  • CELC 0.62
  • IONR 0.18
  • MACD
  • CELC 0.05
  • IONR 0.00
  • Stochastic Oscillator
  • CELC 90.17
  • IONR 47.55

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About IONR ioneer Ltd

Ioneer Ltd is a mineral exploration company. The company's focus is on the Rhyolite Ridge Lithium-Boron Project located in Nevada, USA. Geographically, the group has a business presence in Australia and North America. The company's focus is to develop a U.S.-based source of lithium and boron that can be extracted in an environmentally and socially responsible manner, providing two materials that are essential to achieve a sustainable future for the planet.

Share on Social Networks: